We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitation... Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Show more
As filed with the Securities and Exchange Commission on March 11, 2024 Registration No. 333-_____ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington...
http://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent00http://fasb.org/us-gaap/2023#DerivativeLiabilitiesN...
false 0001393434 0001393434 2024-03-11 2024-03-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED...
In Monday’s pre-market trading, U.S. index futures are indicating a downward move, following the worst week for the Dow Jones since October. Investors are keeping an eye on the important...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
Exhibit 24 LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.88 | -8.81763527054 | 9.98 | 10.28 | 8.97 | 1299068 | 9.55766876 | CS |
4 | -1.05 | -10.3448275862 | 10.15 | 11.31 | 8.83 | 2428778 | 9.87063631 | CS |
12 | 4.5 | 97.8260869565 | 4.6 | 11.31 | 3.7599 | 2104823 | 8.01861258 | CS |
26 | 5.95 | 188.888888889 | 3.15 | 11.31 | 1.995 | 1612061 | 6.14956818 | CS |
52 | 3.99 | 78.0821917808 | 5.11 | 11.31 | 1.995 | 1313589 | 5.82360958 | CS |
156 | -7.71 | -45.8655562165 | 16.81 | 19.84 | 1.995 | 1040135 | 6.90423452 | CS |
260 | 5.07 | 125.806451613 | 4.03 | 24.3 | 1.995 | 972500 | 7.71757837 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions